Improving the outlook for myelodysplastic syndrome.
Vicki
V
Brower
D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use*; D001374:Azacitidine / Q000031:analogs & derivatives / Q000627:therapeutic use; D014408:Biomarkers, Tumor; D019175:DNA Methylation / Q000187:drug effects; D000077209:Decitabine; D018450:Disease Progression; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D044127:Epigenesis, Genetic; D006801:Humans; D000077269:Lenalidomide; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy / Q000235:genetics; D008780:Methyltransferases / Q000187:drug effects; D058990:Molecular Targeted Therapy; D009190:Myelodysplastic Syndromes / Q000188:drug therapy* / Q000235:genetics*; D010750:Phosphoproteins / Q000235:genetics; D017354:Point Mutation; D011379:Prognosis; D012326:RNA Splicing / Q000235:genetics*; D000072260:RNA Splicing Factors; D017413:Ribonucleoprotein, U2 Small Nuclear / Q000235:genetics; D018570:Risk Assessment; D017381:Spliceosomes / Q000235:genetics*; D013792:Thalidomide / Q000031:analogs & derivatives / Q000627:therapeutic use
D000964:Antimetabolites, Antineoplastic; D014408:Biomarkers, Tumor; D004791:Enzyme Inhibitors; D010750:Phosphoproteins; D000072260:RNA Splicing Factors; D017413:Ribonucleoprotein, U2 Small Nuclear; C112491:SF3B1 protein, human; D013792:Thalidomide; D000077209:Decitabine; D008780:Methyltransferases; D000077269:Lenalidomide; D001374:Azacitidine